Iopamiro (Iopamidol)

Iopamidol contains iodine atoms that strongly absorb X‑rays. When injected intravenously, it distributes throughout the vascular system, increasing the radiodensity of blood and extracellular fluid. This heightened attenuation creates a contrast difference between structures, allowing imaging equipment to produce sharper, more detailed pictures.

The dose of Iopamiro is determined by the prescribing physician based on the specific imaging study, patient weight, renal function, and clinical protocol. Healthcare providers calculate the appropriate volume to achieve optimal contrast enhancement while minimizing risk.

The safety of Iopamiro in pregnancy and lactation has not been definitively established. It should be used only when the diagnostic benefit outweighs any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Iopamiro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iopamiro (iopamidol) is a non‑ionic, low‑osmolality agent, which generally offers a lower incidence of adverse reactions compared with older high‑osmolality contrast media. Compared with other low‑osmolality agents, its safety and imaging performance are comparable, though specific choice may depend on institutional protocols and patient risk factors.

Iopamiro should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the vials from direct sunlight, moisture, and extreme temperatures. Do not freeze the solution, and inspect for particulate matter before use.

Iopamiro is administered as an intravenous injection or infusion by a qualified healthcare professional. The injection rate and volume are tailored to the imaging protocol, and the solution should be administered using aseptic technique to avoid contamination.

The most serious risks include severe allergic reactions such as anaphylaxis, acute kidney injury or contrast‑induced nephropathy, and rare cases of cardiovascular instability. Patients with known iodine allergy, impaired renal function, or uncontrolled hypertension should be closely monitored.

Iopamiro should be avoided in patients with a documented severe hypersensitivity to iodinated contrast media, uncontrolled severe renal impairment, or those who have experienced life‑threatening reactions to similar agents. Clinicians must assess individual risk before administration.